Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mast cell-serotonin sensory axis is a complex neuro-immune signaling circuit rather than a single molecular target. It involves the activation of mast cells, which release serotonin (5-HT) and other mediators that subsequently activate specific serotonin receptors on adjacent sensory nerve endings. This interaction is a critical driver of sensations such as pain and chronic itch, particularly in inflammatory skin and mucosal diseases. While the axis itself is a therapeutic concept, drug development typically focuses on specific components within it, such as the 5-HT3 receptor or mast cell stabilizers. Understanding this axis is vital for developing integrated treatments for conditions like atopic dermatitis and irritable bowel syndrome where immune-to-nerve communication is pathological.
Modulation of mast cell degranulation or antagonism of serotonin receptors (e.g., 5-HT3) on sensory neurons to interrupt neuro-immune signaling.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mast cell-serotonin sensory axis (MCSA).